18 months follow-up of deep molecular response 4.5 (MR(4.5)) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China

INTRODUCTION: Early stable deep molecular response (DMR) to nilotinib is associated with goal of treatment-free remission (TFR) in patients with chronic-phase chronic myeloid leukemia (CML-CP). It is important to early distinguish between patients who can achieve a DMR and those who are fit for TFR....

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Bingbing, Zhang, Yuming, Lin, Haiqing, Lou, Jin, Tu, Chuangqing, Jiang, Yirong, Liu, Xiaolian, Chen, Yan, He, Huiqing, Liu, Zelin, Xie, Xiaoling, Huang, Wangxiang, Pang, Liping, Du, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687434/
https://www.ncbi.nlm.nih.gov/pubmed/38034530
http://dx.doi.org/10.3389/fmed.2023.1267512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687434/
https://www.ncbi.nlm.nih.gov/pubmed/38034530
http://dx.doi.org/10.3389/fmed.2023.1267512

Ejemplares similares